Risankizumab vs Ustekinumab in Patients With Crohn Disease: Trial Results
Risankizumab is an interleukin-23 antagonist; ustekinumab is an interleukin-12 and -23 antagonist.
Risankizumab is an interleukin-23 antagonist; ustekinumab is an interleukin-12 and -23 antagonist.
Researchers examined the risk for herpes zoster among patients with inflammatory bowel disease following COVID-19 infection.
Aponvie is an injectable emulsion formulation of aprepitant.
In their statement, the GI specialists noted that they are familiar with safety issues regarding endoscopy in patients with gastroparesis.
Non-IgE-mediated food allergies are on the rise in children and do not always present with an immediate, anaphylaxis-type reaction
Rebyota is a fecal microbiota suspension for rectal administration.
Each capsule contains 140mg of bismuth subcitrate potassium, 125mg of metronidazole, and 125mg of tetracycline hydrochloride.
Previously, the treatment had been approved for patients 1 year of age and older.
Investigators conducted a systematic review and meta-analysis to assess the safety and efficacy of fecal microbiota transplantation for C difficile infection in pediatric patients.
Researchers evaluated the effects of fiber supplementation on the risk for diarrhea among hospitalized patients receiving enteral nutrition.